
On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.
Lending support to his choice, Citigroup analyst Geoff Meacham maintained a Buy rating for Gilead Sciences on Oct. 8, raising the price target from $125 to $135.